Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
The global Conjugate Vaccine market was valued at US$ 9995.1 million in 2023 and is anticipated to reach US$ 12490 million by 2030, witnessing a CAGR of 3.2% during the forecast period 2024-2030.
Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.
This report aims to provide a comprehensive presentation of the global market for Conjugate Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Conjugate Vaccine.
Report Scope
The Conjugate Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Million Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Conjugate Vaccine market comprehensively. Regional market sizes, concerning products by Type, by End Users, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Conjugate Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by End Users, and by regions.
Market Segmentation
By Company
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
Segment by Type
Hib Vaccine
Meningococcal Vaccine
Pneumococcal Vaccine
Others
Segment by End Users
Children
Adult
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by End Users, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by End Users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Conjugate Vaccine Market Overview
1.1 Product Overview and Scope of Conjugate Vaccine
1.2 Conjugate Vaccine Segment by Type
1.2.1 Global Conjugate Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Hib Vaccine
1.2.3 Meningococcal Vaccine
1.2.4 Pneumococcal Vaccine
1.2.5 Others
1.3 Conjugate Vaccine Segment by End Users
1.3.1 Global Conjugate Vaccine Market Value by End Users: (2024-2030)
1.3.2 Children
1.3.3 Adult
1.4 Global Conjugate Vaccine Market Size Estimates and Forecasts
1.4.1 Global Conjugate Vaccine Revenue 2019-2030
1.4.2 Global Conjugate Vaccine Sales 2019-2030
1.4.3 Global Conjugate Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Conjugate Vaccine Market Competition by Manufacturers
2.1 Global Conjugate Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Conjugate Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Conjugate Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Conjugate Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Conjugate Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Conjugate Vaccine, Product Type & Application
2.7 Conjugate Vaccine Market Competitive Situation and Trends
2.7.1 Conjugate Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Conjugate Vaccine Players Market Share by Revenue
2.7.3 Global Conjugate Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Conjugate Vaccine Retrospective Market Scenario by Region
3.1 Global Conjugate Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Conjugate Vaccine Global Conjugate Vaccine Sales by Region: 2019-2030
3.2.1 Global Conjugate Vaccine Sales by Region: 2019-2024
3.2.2 Global Conjugate Vaccine Sales by Region: 2025-2030
3.3 Global Conjugate Vaccine Global Conjugate Vaccine Revenue by Region: 2019-2030
3.3.1 Global Conjugate Vaccine Revenue by Region: 2019-2024
3.3.2 Global Conjugate Vaccine Revenue by Region: 2025-2030
3.4 North America Conjugate Vaccine Market Facts & Figures by Country
3.4.1 North America Conjugate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Conjugate Vaccine Sales by Country (2019-2030)
3.4.3 North America Conjugate Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Conjugate Vaccine Market Facts & Figures by Country
3.5.1 Europe Conjugate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Conjugate Vaccine Sales by Country (2019-2030)
3.5.3 Europe Conjugate Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Conjugate Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Conjugate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Conjugate Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Conjugate Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Conjugate Vaccine Market Facts & Figures by Country
3.7.1 Latin America Conjugate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Conjugate Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Conjugate Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Conjugate Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Conjugate Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Conjugate Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Conjugate Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Conjugate Vaccine Sales by Type (2019-2030)
4.1.1 Global Conjugate Vaccine Sales by Type (2019-2024)
4.1.2 Global Conjugate Vaccine Sales by Type (2025-2030)
4.1.3 Global Conjugate Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Conjugate Vaccine Revenue by Type (2019-2030)
4.2.1 Global Conjugate Vaccine Revenue by Type (2019-2024)
4.2.2 Global Conjugate Vaccine Revenue by Type (2025-2030)
4.2.3 Global Conjugate Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Conjugate Vaccine Price by Type (2019-2030)
5 Segment by End Users
5.1 Global Conjugate Vaccine Sales by End Users (2019-2030)
5.1.1 Global Conjugate Vaccine Sales by End Users (2019-2024)
5.1.2 Global Conjugate Vaccine Sales by End Users (2025-2030)
5.1.3 Global Conjugate Vaccine Sales Market Share by End Users (2019-2030)
5.2 Global Conjugate Vaccine Revenue by End Users (2019-2030)
5.2.1 Global Conjugate Vaccine Revenue by End Users (2019-2024)
5.2.2 Global Conjugate Vaccine Revenue by End Users (2025-2030)
5.2.3 Global Conjugate Vaccine Revenue Market Share by End Users (2019-2030)
5.3 Global Conjugate Vaccine Price by End Users (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Conjugate Vaccine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Conjugate Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Conjugate Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Merck
6.4.1 Merck Corporation Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Conjugate Vaccine Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Walvax Biotechnology
6.5.1 Walvax Biotechnology Corporation Information
6.5.2 Walvax Biotechnology Description and Business Overview
6.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Walvax Biotechnology Conjugate Vaccine Product Portfolio
6.5.5 Walvax Biotechnology Recent Developments/Updates
6.6 Royal (Wuxi) Bio-Pharmaceutical
6.6.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information
6.6.2 Royal (Wuxi) Bio-Pharmaceutical Description and Business Overview
6.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio
6.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
6.7 Bharat Biotech
6.6.1 Bharat Biotech Corporation Information
6.6.2 Bharat Biotech Description and Business Overview
6.6.3 Bharat Biotech Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bharat Biotech Conjugate Vaccine Product Portfolio
6.7.5 Bharat Biotech Recent Developments/Updates
6.8 Zhifei Biologic
6.8.1 Zhifei Biologic Corporation Information
6.8.2 Zhifei Biologic Description and Business Overview
6.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Zhifei Biologic Conjugate Vaccine Product Portfolio
6.8.5 Zhifei Biologic Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Conjugate Vaccine Industry Chain Analysis
7.2 Conjugate Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Conjugate Vaccine Production Mode & Process
7.4 Conjugate Vaccine Sales and Marketing
7.4.1 Conjugate Vaccine Sales Channels
7.4.2 Conjugate Vaccine Distributors
7.5 Conjugate Vaccine Customers
8 Conjugate Vaccine Market Dynamics
8.1 Conjugate Vaccine Industry Trends
8.2 Conjugate Vaccine Market Drivers
8.3 Conjugate Vaccine Market Challenges
8.4 Conjugate Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
*If Applicable.